SCHEMBL1609623

SCHEMBL1609623

c1ccc(CCC2CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.58
MAOB P27338 1/20 0.58
CARM1 Q86X55 1/20 0.54
PRMT6 Q96LA8 1/20 0.54
CTSL P07711 1/20 0.53
CTSB P07858 1/20 0.53
CTSS P25774 1/20 0.53
CTSK P43235 1/20 0.53
CTSC P53634 1/20 0.53
SLC18A2 Q05940 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7756938 0.91 OPRM1 (0.58) MAOAMAOBCTSSCTSKSLC18A2
SCHEMBL705394 0.91 CTSS (0.56) MAOAMAOBCTSSCTSKSLC18A2
SCHEMBL16499614 0.89 MAOA (0.50) MAOAMAOBCARM1PRMT6CTSL
Benzenethiol SCHEMBL4798128 0.89 MAOA (0.50) MAOAMAOBCARM1PRMT6CTSL
SCHEMBL16499700 0.89 MAOA (0.50) MAOAMAOBCARM1PRMT6CTSL
SCHEMBL9163690 0.89 CARM1 (0.51) MAOAMAOBCARM1PRMT6SLC18A2
SCHEMBL10091167 0.89 ACHE (0.53) MAOAMAOBCARM1PRMT6SLC18A2
SCHEMBL7769751 0.89 TDP1 (0.52) MAOAMAOBCARM1PRMT6CTSL
SCHEMBL16499615 0.89 MAOA (0.50) MAOAMAOBCARM1PRMT6CTSL
SCHEMBL19188155 0.89 MAOA (0.50) MAOAMAOBCARM1PRMT6CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150328230-A1 CLEARANCE OF AMYLOID BETA SYNAPTEC DEVELOPMENT LLC (US) 2015-11-19 US claimed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP claimed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO claimed
US-10759741-B2 Separating a solvent from a nickel catalyst by distillation INVISTA NORTH AMERICA S.A R.L. (US) 2020-09-01 US disclosed
CN-108017559-A Phenyl ring derivative and its application in medicine 四川海思科制药有限公司 2018-05-11 CN disclosed
CN-101979394-B A method to inhibit ethylene responses in plants ROHM & HAAS 2013-04-03 CN disclosed
EP-2520570-A1 AMINOPYRIDINE COMPOUND Ube Industries, Ltd. (JP) 2012-11-07 EP disclosed
US-20120259123-A1 AMINOPYRIDINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2012-10-11 US disclosed
US-20110086759-A1 CHEMICAL COMPOUNDS SYNGENTA CROP PROTECTION, INC. (US) 2011-04-14 US disclosed
CN-101979394-A A method to inhibit ethylene responses in plants ROHM & HAAS 2011-02-23 CN disclosed
EP-2237669-A2 CHEMICAL COMPOUNDS Syngenta Limited (GB) 2010-10-13 EP disclosed
EP-0677039-B1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE ABBOTT LAB (US) 1999-03-10 EP disclosed
US-5831115-A CYCLOBUTANECARBOXAMIDES ABBOTT LABORATORIES (US) 1998-11-03 US disclosed
US-5783593-A FUNGICIDE; ANTICHOLESTEROL AGENT ABBOTT LABORATORIES (US) 1998-07-21 US disclosed
EP-0821665-A1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE Abbott Laboratories (US) 1998-02-04 EP disclosed
WO-1996034851-A1 BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE ABBOTT LABORATORIES (US) 1996-11-07 WO disclosed
WO-1996034850-A1 CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE ABBOTT LABORATORIES (US) 1996-11-07 WO disclosed
WO-1996033159-A1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE ABBOTT LABORATORIES (US) 1996-10-24 WO disclosed
EP-0677039-A1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE Abbott Laboratories (US) 1995-10-18 EP disclosed
WO-1995012572-A1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE ABBOTT LABORATORIES (US) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086759-A1 CHEMICAL COMPOUNDS DDT, PNPO, CBR3 MAOA 554/4885MAOB 421/4885CARM1 1024/4885
US-20150328230-A1 CLEARANCE OF AMYLOID BETA BACE1, APP, BCHE MAOA 864/4885MAOB 701/4885CARM1 196/4885
US-10759741-B2 Separating a solvent from a nickel catalyst by distillation ALKBH3, IDH3B, IDH3A MAOA 4352/4885MAOB 3581/4885CARM1 2173/4885
US-20120259123-A1 AMINOPYRIDINE COMPOUND PTGIS, QDPR, PTGIR MAOA 1686/4885MAOB 1298/4885CARM1 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.